SG10201903823QA - Methods and compositions relating to microbial treatment and diagnosis of disorders - Google Patents

Methods and compositions relating to microbial treatment and diagnosis of disorders

Info

Publication number
SG10201903823QA
SG10201903823QA SG10201903823QA SG10201903823QA SG10201903823QA SG 10201903823Q A SG10201903823Q A SG 10201903823QA SG 10201903823Q A SG10201903823Q A SG 10201903823QA SG 10201903823Q A SG10201903823Q A SG 10201903823QA SG 10201903823Q A SG10201903823Q A SG 10201903823QA
Authority
SG
Singapore
Prior art keywords
methods
disorders
diagnosis
microbial treatment
compositions relating
Prior art date
Application number
SG10201903823QA
Other languages
English (en)
Inventor
Colleen Cutcliffe
John Eid
James Bullard
Marcus Schicklberger
Original Assignee
Whole Biome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whole Biome Inc filed Critical Whole Biome Inc
Publication of SG10201903823QA publication Critical patent/SG10201903823QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
SG10201903823QA 2014-10-31 2015-10-30 Methods and compositions relating to microbial treatment and diagnosis of disorders SG10201903823QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073912P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
SG10201903823QA true SG10201903823QA (en) 2019-05-30

Family

ID=55858436

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703395PA SG11201703395PA (en) 2014-10-31 2015-10-30 Methods and compositions relating to microbial treatment and diagnosis of disorders
SG10201903823QA SG10201903823QA (en) 2014-10-31 2015-10-30 Methods and compositions relating to microbial treatment and diagnosis of disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201703395PA SG11201703395PA (en) 2014-10-31 2015-10-30 Methods and compositions relating to microbial treatment and diagnosis of disorders

Country Status (8)

Country Link
US (11) US9486487B2 (zh)
EP (2) EP3881680A1 (zh)
JP (1) JP6868562B2 (zh)
CN (2) CN113730442A (zh)
CA (1) CA2964480A1 (zh)
GB (1) GB2551642B (zh)
SG (2) SG11201703395PA (zh)
WO (1) WO2016070151A1 (zh)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11273187B2 (en) * 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11419903B2 (en) * 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US10881674B2 (en) * 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
MX2017008449A (es) 2014-12-23 2017-10-12 4D Pharma Res Ltd Polipeptido de pirina y modulacion inmune.
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
WO2016168370A1 (en) * 2015-04-14 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
CA2988695A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
WO2017035426A1 (en) * 2015-08-27 2017-03-02 The Procter & Gamble Company Bifidobacterium longum
CA3005985A1 (en) 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics 0finfectious disease and other health conditions associated with antibiotic usage
PT3209310T (pt) 2015-11-20 2018-04-20 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
BR112018013292A2 (pt) 2015-12-31 2018-12-04 Caelus Pharmaceuticals B V ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii?
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
PL3411052T3 (pl) * 2016-02-04 2021-03-08 Universiteit Gent Zastosowanie skupisk drobnoustrojów dla zdrowia ludzi i zwierząt
CN107080756B (zh) * 2016-02-15 2020-08-25 深圳华大生命科学研究院 链球菌属益生菌在预防和/或治疗糖尿病及其相关疾病中的应用
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
AU2017228502C1 (en) 2016-03-04 2021-09-16 The Regents Of The University Of California Microbial consortium and uses thereof
US11116804B2 (en) 2016-03-14 2021-09-14 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
ES2954147T3 (es) 2016-04-15 2023-11-20 Baylor College Medicine Lactobacillus reuteri mm4-1a para usar en el tratamiento o la prevención de trastornos del espectro autista
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR101799829B1 (ko) 2016-07-11 2017-11-21 한국생명공학연구원 퇴행성 뇌질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도
EP3483256A4 (en) * 2016-07-11 2019-12-04 Korea Research Institute of Bioscience and Biotechnology AKKERMANSIA MUCINIPHILA TRIBE WITH EFFECT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES OR METABOLIC DISEASES AND USE THEREOF
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
JP6862464B2 (ja) * 2016-09-06 2021-04-21 ビージーアイ シェンチェン フィーカリバクテリウム・ロンガム（Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｌｏｎｇｕｍ）およびその使用
JP7068287B2 (ja) * 2016-10-13 2022-05-16 ビオメリュー メタゲノム試料中の病原体の同定と抗生物質の特徴づけ
IT201600109507A1 (it) * 2016-10-28 2018-04-28 Probiotical Spa Composizione per il trattamento preventivo o curativo dei disturbi epatici
FR3059678A1 (fr) * 2016-12-05 2018-06-08 Ecole Normale Superieure Lyon Bacteries lactiques utiles pour traiter les maladies metaboliques, notamment le diabete de type 2
CA3045026A1 (en) * 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
US10811126B2 (en) * 2016-12-14 2020-10-20 Tracy Warren System and methods for developing and using a microbiome-based action component for patient health
US11806372B2 (en) * 2017-04-21 2023-11-07 The Broad Institute, Inc. Methods of treating and diagnosing IBD associated with r. gnavus and/or r. gnavus group IBD colonization
PL3630136T3 (pl) 2017-05-22 2021-09-13 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
DK3600364T3 (da) 2017-06-14 2020-08-31 4D Pharma Res Ltd Sammensætninger omfattende en bakteriestamme af slægten megasphaera og anvendelser deraf
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
JP2020529478A (ja) * 2017-08-04 2020-10-08 セカンド ゲノム インコーポレイテッド バイオ治療薬としてのロゼブリア・ホミニス（ｒｏｓｅｂｕｒｉａ ｈｏｍｉｎｉｓ）、ユーバクテリウム・エリゲンス（ｅｕｂａｃｔｅｒｉｕｍ ｅｌｉｇｅｎｓ）、およびこれらの組み合わせ
JP2020532515A (ja) * 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
CN111970933A (zh) * 2017-10-18 2020-11-20 埃斯库斯生物科技股份公司 通过施用微生物或其纯化菌株的合成生物集合体来提高禽类产量
ES2924041T3 (es) * 2018-03-02 2022-10-04 Acad Medisch Ct Materia fecal para la prevención o el tratamiento de enfermedades autoinmunes
US20230158082A1 (en) * 2018-03-06 2023-05-25 Md Healthcare Inc. Nanovesicles derived from coprococcus sp. bacteria, and use thereof
EP3773645A4 (en) 2018-04-10 2021-11-24 Siolta Therapeutics, Inc. MICROBIAL CONSORTIA
CN112236155A (zh) * 2018-05-31 2021-01-15 深圳华大生命科学研究院 一种组合物及其应用
US20210268037A1 (en) * 2018-06-25 2021-09-02 Second Genome, Inc. Anaerostipes hadrus for use in promoting health
CN110638838B (zh) * 2018-06-26 2021-07-06 瑞微（深圳）生物科技有限公司 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
WO2020018949A2 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CN108567799A (zh) * 2018-08-01 2018-09-25 中国人民解放军总医院 一种全粪菌复合胶囊及其制备方法和应用
WO2020068827A1 (en) * 2018-09-24 2020-04-02 Pendulum Therapeutics, Inc. Microbial compositions and methods of use
EP3646857A1 (en) * 2018-11-01 2020-05-06 Evonik Operations GmbH Colonic delivery system for microorganisms
JP2022510780A (ja) * 2018-11-05 2022-01-28 ザ・ユニバーシティ・オブ・シカゴ 感染性疾患、自己免疫疾患、およびアレルギー性疾患を治療するための方法および組成物
US11877981B2 (en) 2018-12-05 2024-01-23 The Procter & Gamble Company Container for personal health compositions
WO2020113580A1 (zh) * 2018-12-07 2020-06-11 深圳华大生命科学研究院 人粪厌氧棒形菌在预防和/或治疗代谢性疾病中的用途
WO2020123559A1 (en) * 2018-12-11 2020-06-18 Glyciome, Llc Topical, isotonic compositions for genital use
EP3669944B1 (en) * 2018-12-21 2023-12-20 Salomon Amar Use of akkermansia in the treatment of oral diseases
US20200215127A1 (en) * 2019-01-09 2020-07-09 LifeBidge Health, Inc. Targeted synbiotic therapy for dysbiosis-related intestinal and extra-intestinal disorders
CN109666615B (zh) * 2019-02-20 2021-03-19 无限极（中国）有限公司 一种益生菌组合物及其应用
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
EP4010315A4 (en) * 2019-08-09 2023-11-15 The Regents of the University of California COMPOSITIONS AND METHODS OF TREATING METABOLIC DISEASE
EP4025714A4 (en) * 2019-09-02 2023-10-11 My-Or Diagnostics Ltd. SKIN MICROBIOME MONITORING TO IMPROVE SYSTEMIC HEALTH
CN112538439B (zh) * 2019-09-04 2022-03-15 欧斐生 一种植物乳杆菌及其制备植物性凝态酸奶、改善肠道菌相的用途
CA3153884A1 (en) 2019-10-07 2021-04-15 Nikole KIMES Therapeutic pharmaceutical compositions
KR102136559B1 (ko) * 2019-10-24 2020-07-22 건국대학교 산학협력단 케피어를 포함하는 반려동물용 식품 조성물 및 사료 첨가제
US20220395541A1 (en) * 2019-12-20 2022-12-15 Pendulum Therapeutics, Inc. Methods and Compositions Comprising a Bacteria with Increased Viability and Faster Revivability
IL271775A (en) * 2019-12-31 2021-06-30 Biomica Ltd A microbial consortium and its uses
CA3164170A1 (en) * 2020-01-13 2021-07-22 Scioto Biosciences, Inc. Methods for treating or ameliorating autism and related disorders
WO2022163824A1 (ja) * 2021-01-29 2022-08-04 アニコム ホールディングス株式会社 肥満の予測方法
CN113046274B (zh) * 2021-04-26 2022-09-27 江南大学 缓解辣椒素致胃肠损伤的罗伊氏乳杆菌及其应用
WO2023002461A1 (en) 2021-07-23 2023-01-26 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
CN114246886B (zh) * 2021-12-24 2023-05-30 山西大学 规则粪球菌在制备预防和治疗急性结肠炎的制剂中的应用
CN114774338B (zh) * 2022-03-29 2023-08-08 北京航空航天大学 一种产丁酸的益生菌及其构建方法和应用
EP4309662A1 (en) * 2022-07-19 2024-01-24 Enbiosis Biotechnology Limited Microorganisms converting inositol to butyrate
CN117106849B (zh) * 2023-10-24 2024-02-02 山东省科霖检测有限公司 一种城市空气微生物生态分布监测方法

Family Cites Families (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1014986A (en) 1910-01-03 1912-01-16 Alfred J Ware Printing-machine.
US1014987A (en) 1910-12-12 1912-01-16 B L Shrader Gang-plow.
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5143845A (en) * 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
EP0433299B1 (en) 1988-08-02 1998-05-06 Gastro Services Pty. Limited (ACN 002 994 890) Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
JPH08298982A (ja) * 1995-05-02 1996-11-19 Aasu Giken:Kk 複合微生物製剤
AU744156B2 (en) 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
HUP0103502A2 (hu) 1998-09-17 2002-01-28 Baxter Healthcare S.A. Streptococcus Cbéta-fehérje készítmények
BR9916062A (pt) 1998-12-11 2002-09-24 Urex Biotech Inc Administração oral de lactobacillus para o tratamento e prevenção de infecção urogenital
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
ATE425244T1 (de) 1999-08-05 2009-03-15 Nestle Sa Bifidobacteria zum vorbeugen von diarrhöe infolge pathogener bakterien
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
DE10043151A1 (de) * 2000-08-31 2002-03-28 Peter Steinruecke Knochenzement mit antimikrobieller Wirksamkeit
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
DE60222856T2 (de) 2001-02-06 2008-07-24 Société des Produits Nestlé S.A. Endotoxin-bindung durch milchsäurebakterien und bifidobacteria
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
US20050069505A1 (en) 2002-02-21 2005-03-31 Lionel Breton Orally administrable composition for the photoprotection of the skin
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (en) 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
JP2008503563A (ja) 2004-06-23 2008-02-07 ロレアル 敏感及び／又は乾燥肌の予防及び／又は処置に有用な方法及び組成物
CA2471142A1 (fr) 2004-06-25 2005-12-25 Pierre Marcotte Ressort a comportement controle
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
WO2006050166A2 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
JP5565991B2 (ja) 2004-12-15 2014-08-06 株式会社島津製作所 微生物菌種推定システム及び方法
US8728794B2 (en) 2004-12-28 2014-05-20 Meiji Seika Pharma Co., Ltd. Strain conferring anti-disease properties to host and bacterial cell composition
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20060223153A1 (en) 2005-04-05 2006-10-05 Luca Technologies, Llc Generation of materials with enhanced hydrogen content from anaerobic microbial consortia
US8501463B2 (en) 2005-05-03 2013-08-06 Anaerobe Systems Anaerobic production of hydrogen and other chemical products
JP2006314219A (ja) * 2005-05-11 2006-11-24 Asahi Breweries Ltd 腸内細菌を利用した胆汁酸の吸着方法、および胆汁酸吸着物質
JP2007031291A (ja) * 2005-07-22 2007-02-08 Ace Bio Product Kk 体重増加抑制剤及び体重増加抑制飲料
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
CN101410128A (zh) * 2006-01-27 2009-04-15 丹尼斯科公司 益生微生物用于治疗和预防肥胖及相关病症的用途
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
JP2009537547A (ja) 2006-05-18 2009-10-29 バイオバランス エルエルシー 生物学的治療組成物およびその使用
CN1850047A (zh) 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US7867578B2 (en) * 2006-06-28 2011-01-11 Applied Materials, Inc. Method for depositing an amorphous carbon film with improved density and step coverage
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US20110020283A1 (en) 2007-02-22 2011-01-27 Schrezenmeir Juergen Probiotic, gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in humans
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
CN101688171B (zh) 2007-03-28 2013-03-27 营养健康有限公司 益生双歧杆菌菌株
EP2142635B1 (en) 2007-05-03 2018-05-23 Tobias Olofsson Novel bacteria isolated from the honey producing tract of honey bees
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
EP1992351B1 (en) 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
US20090010891A1 (en) * 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
US20090010892A1 (en) * 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
WO2009018447A2 (en) 2007-07-31 2009-02-05 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2192909A2 (en) 2007-10-01 2010-06-09 University College Cork-National University of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2343499B1 (es) 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
US20110189149A1 (en) 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
CN102089422B (zh) 2008-07-11 2013-07-17 科.汉森有限公司 新的益生长双歧杆菌
WO2010030781A2 (en) 2008-09-10 2010-03-18 Numed International, Inc. Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
US20100087481A1 (en) 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
EP2352389B1 (en) 2008-11-11 2016-01-06 Alimentary Health Limited Bifidobacterium longum
JP5606672B2 (ja) 2008-11-26 2014-10-15 太陽化学株式会社 シンバイオティクスを利用した腸内環境調整方法
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
EP2400839B1 (en) * 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US20100086981A1 (en) 2009-06-29 2010-04-08 Qteros, Inc. Compositions and methods for improved saccharification of biomass
ES2528602T3 (es) * 2009-03-25 2015-02-10 Chr. Hansen A/S Uso de un probiótico para la regulación del peso corporal
US20120027737A1 (en) 2009-03-25 2012-02-02 Chr-Hansen A/S Use of probiotics to ameliorate diet-induced insulin resistance
CN102439048B (zh) 2009-05-07 2015-03-25 泰莱配料法国有限公司 组合物及制备α-(1,2)-支化的α-(1,6)葡聚寡糖的方法
EP2429538B1 (en) 2009-05-11 2015-10-21 Nestec S.A. Non-replicating bifidobacterium longum ncc2705 and immune disorders
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
ES2729765T3 (es) 2009-06-19 2019-11-06 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
WO2011011094A1 (en) 2009-07-24 2011-01-27 Dowd Scot E Universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
CN102470152A (zh) 2009-07-30 2012-05-23 丹尼斯科公司 用于治疗内毒素血症的乳酸菌和双歧杆菌
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
KR100962365B1 (ko) 2009-10-07 2010-06-10 주식회사 대일 활어수송용 컨테이너
BR112012011294B1 (pt) 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
EP2513292B1 (en) 2009-12-16 2017-09-06 Probiotical S.p.A. Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a pharmaceutical composition
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
JP5578375B2 (ja) 2010-02-10 2014-08-27 日環科学株式会社 好熱性微生物を用いた混合物、溶解液、及び医薬品
AU2011223049B2 (en) 2010-03-01 2015-06-18 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
CN102939392A (zh) 2010-03-01 2013-02-20 国家农艺研究院 肥胖的诊断方法
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
JP5799083B2 (ja) * 2010-04-12 2015-10-21 エルジー エレクトロニクス インコーポレイティド 多重アンテナ支援無線通信システムにおいて効率的なフィードバック方法及び装置
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9439933B2 (en) 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
ES2744576T3 (es) 2010-06-30 2020-02-25 Nestle Sa Uso de ácido cicórico y bacteria láctica en suplemento alimenticio para aclarar y/o blanquear el tono de la piel
WO2012021678A2 (en) * 2010-08-12 2012-02-16 The Administrators Of The Tulane Educational Fund Isolated bacteria, methods for use, and methods for isolation
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
AU2011299285B2 (en) 2010-09-10 2017-01-05 Ntcd, Llc Environmental Clostridial bacteriotherapy and related formulations and methods of manufacture and use
EP2944690B1 (en) 2010-10-11 2017-12-20 Jennewein Biotechnologie GmbH Novel fucosyltransferases and their applications
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
MX2013007737A (es) * 2010-12-29 2013-07-24 Nestec Sa Fibra y probioticos para reducir sintomas intestinales relacionados con estres.
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US9504739B2 (en) 2011-03-01 2016-11-29 Quorum Innovations, Llc Method of identifying a biologically-active composition from a biofilm
SG193348A1 (en) 2011-03-09 2013-10-30 Univ Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
CN102254089A (zh) 2011-04-18 2011-11-23 王钰 一种体系仿真方法和系统
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
WO2013032744A2 (en) 2011-08-17 2013-03-07 Nume Health, Llc Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum
EP2744888B1 (en) 2011-08-18 2017-12-13 Chr. Hansen A/S Method for purifying bacterial cells
SG11201401811WA (en) 2011-08-30 2014-09-26 Amc Amsterdam Method for preventing and/or treating insulin resistance
EP2744890A4 (en) 2011-09-14 2015-07-08 Univ Kingston METHOD FOR TREATING DISORDERS OF THE GASTROINTESTINAL DEVICE
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
WO2013067185A1 (en) 2011-11-02 2013-05-10 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
CA2854398A1 (en) 2011-11-04 2013-05-10 General Mills, Inc. Methods and compositions for modulating gastrointestinal bacteria to promote health
EP2785828B1 (en) 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2013084971A1 (ja) 2011-12-07 2013-06-13 カルピス株式会社 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤
EP2828375B1 (en) 2012-01-19 2017-11-22 University College Cork-National University of Ireland, Cork Gaba-producing culturable bacteria derived from the human gastrointestinal tract
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) * 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
EP2885396B1 (en) 2012-08-20 2020-02-19 Chr. Hansen A/S Method for optimizing a process for freeze drying a bacteria-containing concentrate
KR20150118084A (ko) * 2012-09-20 2015-10-21 프로테라 인코포레이티드 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
US20150283144A1 (en) 2012-11-01 2015-10-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
EP3967315A1 (en) 2012-11-19 2022-03-16 Université catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
PT3628161T (pt) 2012-11-23 2023-05-15 Seres Therapeutics Inc Composições bacterianas sinergísticas e métodos de produção e utilização das mesmas
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014088982A1 (en) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
EP2988761A1 (en) 2013-03-05 2016-03-02 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
CN105120847B (zh) * 2013-03-14 2018-12-28 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
AU2014232370B2 (en) 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10716802B2 (en) 2013-03-15 2020-07-21 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
WO2014190251A1 (en) 2013-05-24 2014-11-27 Genomatica, Inc. Microorganisms and methods for producing (3r)-hydroxybutyl (3r)-hydroxybutyrate
WO2014201037A2 (en) 2013-06-10 2014-12-18 New York University Methods for manipulating immune responses by altering microbiota
KR101470513B1 (ko) 2013-07-17 2014-12-08 주식회사 아모그린텍 대전류 직류중첩특성 및 코어손실 특성이 우수한 연자성 코어 및 그의 제조방법
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
WO2015051323A1 (en) 2013-10-03 2015-04-09 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
US10058576B2 (en) 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319525D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
CN116370507A (zh) 2013-11-25 2023-07-04 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
KR20150066772A (ko) 2013-12-09 2015-06-17 주식회사 쎌바이오텍 신규한 유산균 및 이를 포함하는 영유아의 설사병 예방 또는 치료용 조성물
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015089674A1 (en) 2013-12-20 2015-06-25 9286-3620 Québec Inc. Protein-based enteric coating for oral dosage forms
JP6527522B2 (ja) 2013-12-20 2019-06-05 ネステク ソシエテ アノニム 腸内病原菌を低減するための栄養組成物
US20160354417A1 (en) 2014-02-04 2016-12-08 Micro-Nature Llc Systems, methods, and compositions relating to combiomics
WO2015120471A1 (en) 2014-02-10 2015-08-13 The Johns Hopkins University Devices for and methods of treatment of metabolic syndromes
BR112016018283A2 (pt) 2014-02-14 2017-08-08 Vesale Pharma Sa Composição que compreende bifidobacterium animalis ssp. lactis
US20160367661A1 (en) 2014-02-27 2016-12-22 Yale University NLRP6 Inflammasome Intestinal Epithelium Mucus Secretion
US20150246081A1 (en) 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
US20150374760A1 (en) 2014-04-09 2015-12-31 Jose U. Scher Methods for treating psoriasis and psoriatic arthritis
PL3138031T3 (pl) 2014-04-28 2023-04-11 Yeda Research And Development Co., Ltd. Sposób i urządzenie do przewidywania odpowiedzi na pokarm
ES2870658T3 (es) 2014-04-28 2021-10-27 Yeda Res & Dev Respuesta del microbioma a agentes
FI127483B (en) 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product
MX2014009044A (es) 2014-07-25 2016-01-25 Polioles S A De C V Nuevas moléculas derivadas de 2-fenil-imidazolinas fosforiladas, con alta estabilidad del anillo imidazolina y alta efectividad como inhibidores de corrosión.
CN106659226A (zh) 2014-08-18 2017-05-10 雀巢产品技术援助有限公司 用于降低以后生命中肥胖风险的益生元
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3209308B1 (en) 2014-10-24 2022-08-03 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
US11135181B2 (en) 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CA2967233A1 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Method of analyzing microbiome
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20170326186A1 (en) 2014-11-26 2017-11-16 Probiotical S.P.A. Strains of lactobacillus and bifidobacteria for the maintenance of a long-lasting homeostasis condition in a human body
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
EP3242957B1 (en) 2015-01-09 2020-03-11 Wageningen Universiteit Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
SG11201705953XA (en) 2015-01-23 2017-08-30 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
WO2016139217A1 (en) 2015-03-04 2016-09-09 Ab-Biotics, S.A. Composition comprising anaerobically cultivated human intestinal microbiota
SG10202101108RA (en) 2015-03-13 2021-03-30 Evolve Biosystems Inc Compositions that metabolize or sequester free sugar monomers and uses thereof
US20160271189A1 (en) 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US9913800B2 (en) 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
WO2016174677A1 (en) 2015-04-28 2016-11-03 Yeda Research And Development Co. Ltd. Use of microbial metabolites for treating diseases
JP6925280B2 (ja) 2015-05-06 2021-08-25 ヴァーヘニンゲン ユニバーシテイト アッカーマンシアの培養方法
EA201700507A1 (ru) 2015-05-06 2018-05-31 Университе Католик Де Лувен Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
KR20180010237A (ko) 2015-05-21 2018-01-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 건강 증진을 위한 박테리아 집단
KR101589464B1 (ko) 2015-05-21 2016-02-01 주식회사 쎌바이오텍 신규한 비피더스 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물
KR101589466B1 (ko) 2015-05-21 2016-02-01 주식회사 쎌바이오텍 성장 촉진을 위한 비피도박테리움 롱굼 cbt bg7 균주 및 이를 포함하는 성장촉진용 기능성 식품 조성물
MX2017015433A (es) 2015-05-30 2018-06-19 Japan Eco Science Co Ltd Probiotico o prebiotico, metodo para la produccion del mismo, preparacion microbiana, alimento saludable y medicina.
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
US20160355847A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Of Agriculture Novel Clostridium Species That Converts Wheat Straw and Switchgrass Hydrolysates Into Butyric Acid
US20180153944A1 (en) 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
GB201514303D0 (en) 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Bifidobacteria for treating cardiac conditions
WO2017019273A1 (en) 2015-07-29 2017-02-02 Advanced Bionutrition Corporation Stable dry probiotic compositions for special dietary uses
US11090354B2 (en) 2015-08-06 2021-08-17 The Johns Hopkins University Composition and method for treatment of metabolic disorders
US10300043B2 (en) 2015-08-12 2019-05-28 Mayo Foundation For Medical Education And Research Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CA2995786A1 (en) 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
CN105030841A (zh) 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
EP3334437A1 (en) 2015-08-25 2018-06-20 Kaleido Biosciences, Inc. Glycan compositions and uses thereof
WO2017035426A1 (en) 2015-08-27 2017-03-02 The Procter & Gamble Company Bifidobacterium longum
WO2017032897A1 (en) 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
JP2018531908A (ja) 2015-09-04 2018-11-01 メモリアル スローン ケタリング キャンサー センター 癌の再発のリスクを検出するための方法及び組成物
CN114276960A (zh) 2015-09-10 2022-04-05 卢万天主教大学 经巴氏灭菌的艾克曼菌用于治疗代谢病症的用途
WO2017047968A1 (ko) 2015-09-15 2017-03-23 경희대학교 산학협력단 다양한 기능성을 가진 신규 유산균 및 이의 용도
US10537597B2 (en) 2015-10-05 2020-01-21 Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos Use of Akkermansia muciniphila for treating inflammatory conditions
KR20180056775A (ko) 2015-10-07 2018-05-29 갈데르마 리써어치 앤드 디벨로프먼트 유산균 함유 조성물 및 아토피 피부염을 치료하기 위한 이의 용도
WO2017063066A1 (en) 2015-10-15 2017-04-20 Natura Cosméticos S.A. Cosmetic composition having probiotic bacteria
CA3003138A1 (en) 2015-10-26 2017-05-04 Crestovo Holdings Llc Compositions and methods for fecal microbiota-related therapy
IL298281A (en) 2015-11-03 2023-01-01 Brigham & Womens Hospital Inc Medical microbiota for the treatment and/or prevention of food allergy
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3380108T3 (pl) 2015-11-24 2023-03-27 Seres Therapeutics, Inc. Zaprojektowane kompozycje bakteryjne
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
AU2016368527B2 (en) 2015-12-11 2023-01-12 Precisionbiotics Group Limited Bifidobacterium longum for treating obesity and associated metabolic disorders
US10548844B2 (en) 2015-12-14 2020-02-04 Massachusetts Institute Of Technology pH-responsive mucoadhesive polymeric encapsulated microorganisms
ES2962302T3 (es) 2015-12-14 2024-03-18 Metabogen Ab Tratamiento de la colestasis intrahepática y hepatopatías relacionadas
JPWO2017130859A1 (ja) 2016-01-28 2018-11-15 森永乳業株式会社 神経細胞死抑制剤
PL3411052T3 (pl) 2016-02-04 2021-03-08 Universiteit Gent Zastosowanie skupisk drobnoustrojów dla zdrowia ludzi i zwierząt
KR20180113535A (ko) 2016-02-25 2018-10-16 카엘루스 파마슈티컬스 비.브이. 비타민 b12 결핍을 예방 및/또는 치료를 위한 조성물 및 방법
CN109069522A (zh) 2016-03-14 2018-12-21 物产食品科技股份有限公司 肠内丁酸增加剂及丁酸产生菌增殖剂
CA3045026A1 (en) 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
CA3072206A1 (en) 2017-08-14 2019-02-21 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
WO2020068827A1 (en) 2018-09-24 2020-04-02 Pendulum Therapeutics, Inc. Microbial compositions and methods of use
WO2020236979A1 (en) 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
AU2020412484A1 (en) 2019-12-23 2022-08-18 Pendulum Therapeutics, Inc. Compositions comprising microbes and methods of use and making thereof

Also Published As

Publication number Publication date
EP3881680A1 (en) 2021-09-22
GB2551642B (en) 2020-09-23
US20190030096A1 (en) 2019-01-31
US20210386798A1 (en) 2021-12-16
US9486487B2 (en) 2016-11-08
US20200261517A1 (en) 2020-08-20
US10675312B2 (en) 2020-06-09
US11213556B2 (en) 2022-01-04
EP3212001A4 (en) 2018-04-25
CA2964480A1 (en) 2016-05-06
JP6868562B2 (ja) 2021-05-19
GB201707848D0 (en) 2017-06-28
US20170020932A1 (en) 2017-01-26
US10842831B2 (en) 2020-11-24
SG11201703395PA (en) 2017-05-30
US20190070228A1 (en) 2019-03-07
JP2017535597A (ja) 2017-11-30
CN113730442A (zh) 2021-12-03
EP3212001A1 (en) 2017-09-06
US20200261518A1 (en) 2020-08-20
US20190030095A1 (en) 2019-01-31
US11931387B2 (en) 2024-03-19
GB2551642A (en) 2017-12-27
US20160228476A1 (en) 2016-08-11
US10668116B2 (en) 2020-06-02
CN108064132A (zh) 2018-05-22
US20170027996A1 (en) 2017-02-02
WO2016070151A8 (en) 2016-06-30
US11278580B2 (en) 2022-03-22
WO2016070151A9 (en) 2017-06-29
WO2016070151A1 (en) 2016-05-06
US11364270B2 (en) 2022-06-21
US20190070227A1 (en) 2019-03-07
US20200345796A1 (en) 2020-11-05
US10842830B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
EP3270938A4 (en) Methods and compositions relating to microbial treatment and diagnosis of skin disorders
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
WO2015073587A3 (en) Synthetic membrane-receiver complexes
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EP4268860A3 (en) Compositions, devices, kits and methods for attaching stent-containing medical devices to tissue
WO2015173633A3 (en) Hdl therapy markers
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016106343A8 (en) Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
MY193650A (en) Extracellular matrix compositions
WO2016079110A3 (en) Use of enzyme for cleaning
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
WO2017066796A3 (en) Modulators of telomere disease